Michael Wang, MD, discusses the pharmacological profile of KTE-X19 in patients with high- or low-risk relapsed/refractory mantle cell lymphoma in the ZUMA-2 trial.
Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the pharmacological profile of KTE-X19 in patients with high- or low-risk relapsed/refractory mantle cell lymphoma (MCL) in the ZUMA-2 trial (NCT02601313).
In this phase 2 trial, investigators wanted to see whether the chimeric antigen receptor (CAR) T-cell expansion would be similar between patients with high-risk and low-risk disease. The results showed the efficacy was the same for these groups. According to Wang, finding that the efficacy was the same for the patients with low-risk MCL is important because there is now underlying data to correspond to the observation that low-risk and high-risk disease react the same with a CAR T-cell therapy such as KTE-X19; therefore, an anti-CD19 CAR T-cell therapy can overcome high-risk resistance in patients. In his opinion, this is powerful data for this setting.
The pharmacodynamic profiles between patients with low- and high-risk MCL were shown in the poster presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program. Wang says there was a small trend between increased cytokines in the high-risk group, but there was not a statistical difference.
<< View more resources and information regarding mantle cell lymphoma
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More